Genetic variations and haplotypes in TIM-3 gene and the risk of gastric cancer.
OBJECTIVE
T cell immunoglobulin and mucin domain-containing molecule 3 (TIM-3) could weaken the Th1-mediated anti-tumor responses and accelerate the tumor cell proliferation by inhabiting the production of IL-2 or IFN-γ. This study was to assess the association between TIM-3 genetic variations and the development of gastric cancer.


METHODS
Five polymorphisms located in the promoter or encoding region of TIM-3 gene were genotyped in 212 gastric cancer patients and 252 controls who matched with the patients on the frequency of age, gender, smoking, and drinking. Logistic regression was used to determine whether the inherited variations within TIM-3 gene were associated with gastric cancer risk. Linkage disequilibrium and Haplotype analyses were performed by using SHEsis program.


RESULTS
By the individual genotype analysis, three polymorphisms (-574G/T, -882C/T, and -1516G/T) within TIM-3 gene were significantly associated with gastric cancer in the study population [ORs (95% CIs): 2.74 (1.21-6.20), 3.19 (1.29-7.91), and 2.03 (1.15-3.59); respectively]. Among the gastric cancer patients, the relationship between the -1516 polymorphic genotype and the distant metastasis of tumor was found (OR = 2.21, 95% CI = 1.05-4.63). Under the analysis of haplotypes, an even stronger association with haplotype TTGCT was observed in gastric cancer risk (OR = 5.57, 95% CI: 1.04-29.80, P = 0.024).


CONCLUSIONS
These results indicated that the three genetic variations within the TIM-3 gene promoter may be associated with the increased susceptibility to gastric cancer, especially among the haplotypes with the risk.
Cao
Bangwei
B
Department of Oncology, Beijing Friendship Hospital, Capital Medical University, Beijing, 100050, China.
Zhu
Linzhong
L
Zhu
Shengtao
S
Li
Danping
D
Zhang
Chuanzhen
C
Xu
Changqing
C
Zhang
Shutian
S
D000328:Adult; D000368:Aged; D016022:Case-Control Studies; D005260:Female; D020022:Genetic Predisposition to Disease; D014644:Genetic Variation; D006239:Haplotypes; D000072597:Hepatitis A Virus Cellular Receptor 2; D006801:Humans; D008297:Male; D008565:Membrane Proteins / Q000235:genetics*; D008875:Middle Aged; D020641:Polymorphism, Single Nucleotide; D011401:Promoter Regions, Genetic; D012306:Risk; D013274:Stomach Neoplasms / Q000209:etiology / Q000235:genetics*
C448908:HAVCR2 protein, human; D000072597:Hepatitis A Virus Cellular Receptor 2; D008565:Membrane Proteins
Exp Mol Med. 2004 Jun 30;36(3):274-8
15272240
Cancer Immunol Immunother. 2009 Sep;58(9):1433-40
19169878
Science. 2007 Nov 16;318(5853):1141-3
18006747
Int Arch Allergy Immunol. 2009;150(3):252-60
19494522
Nature. 2002 Jan 31;415(6871):536-41
11823861
Scand J Immunol. 2008 Jan;67(1):63-70
18052965
Hum Immunol. 2009 Jun;70(6):398-402
19332093
Nat Immunol. 2003 Nov;4(11):1102-10
14556006
Cancer Immunol Immunother. 2005 Aug;54(8):729-40
15685448
Cell Res. 2009 Apr;19(4):519-23
19290020
J Immunol. 2008 Dec 1;181(11):7660-9
19017954
Cancer Immunol Immunother. 2005 Feb;54(2):172-8
15248031
J Immunol. 2004 Mar 1;172(5):2778-84
14978077
Best Pract Res Clin Gastroenterol. 2006;20(4):633-49
16997150
Nat Immunol. 2005 Dec;6(12):1245-52
16286920
Biochem Biophys Res Commun. 2006 Dec 15;351(2):571-6
17069754
Expert Opin Ther Targets. 2007 Aug;11(8):1005-9
17665973
Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2006 Feb;23(1):74-7
16456792
Eur J Cancer. 2008 Jul;44(10):1345-89
18280139
Nat Immunol. 2003 Nov;4(11):1093-101
14556005
J Immunol. 2006 Feb 1;176(3):1411-20
16424168
Int Arch Allergy Immunol. 2006;141(4):331-6
16940744